Open Access Open Badges Research

Bendamustine in patients with relapsed or refractory multiple myeloma

M Michael1, I Bruns1, E Bölke2, F Zohren1, A Czibere1, N N Safaian1, F Neumann1, R Haas1, G Kobbe1 and R Fenk1*

Author Affiliations

1 Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Germany

2 Department of Radiooncology, Heinrich-Heine-University, Duesseldorf, Germany

For all author emails, please log on.

European Journal of Medical Research 2010, 15:13-19  doi:10.1186/2047-783X-15-1-13

Published: 29 January 2010



In patients with multiple myeloma, bendamustine monotherapy is effective as 1st and 2nd line therapy. However, data for patients with advanced multiple myeloma is rare.


In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids.


Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively.


In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials.

Bendamustine; multiple myeloma; relapsed/refractory